Hill-Rom outlines optimistic forecasts based on strong 2017 performance

Hill-Rom has outlined optimistic expectations for growth and other financial metrics up to 2020, based on the encouraging momentum it saw during 2017.

The firm expects reported revenue growth to be in the three to four percent range on a compound annual basis from 2017 to 2020 on a constant currency basis, with core revenue growth estimated at four to five percent.

Hill-Rom's 2017 business year concluded on September 30th, with the company generating a $2.74 billion (2.09 billion pounds) total during the 12-month period. This marked a three percent year-on-year increase, or four percent on a constant currency basis.

Key highlights of the year included the acquisition and integration of Mortara, the divestiture of non-strategic assets, and the launch of new products such as the Centrella Smart Plus bed and the Envella air-fluidised therapy bed.

In 2018, revenue is expected to increase by three to four percent on a reported basis and approximately two to three percent on a constant currency basis.

John Greisch, president and chief executive officer of Hill-Rom, said: "We believe Hill-Rom is well-positioned to deliver strong financial and operational performance, and attractive shareholder returns, over the next several years as we continue on our transformational journey and execute on key strategic priorities."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.